Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBN-2397 plus Pembrolizumab in SCCL
NCT05127590Phase 2Unknown
- Sponsor
- Ribon Therapeutics
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of atamparib in squamous cell carcinoma of the lung (SCCL), sponsored by Ribon Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 6 months and Overall Response Rate up to 78 weeks. Status: unknown.
02
Drugs
atamparib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05127590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127590.